Vera Therapeutics (NASDAQ:VERA) Issues Earnings Results

Vera Therapeutics (NASDAQ:VERA - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11, Zacks reports.

Vera Therapeutics Trading Up 1.8 %

Shares of Vera Therapeutics stock traded up $0.52 on Friday, hitting $29.93. 795,417 shares of the company's stock traded hands, compared to its average volume of 908,211. The firm's 50-day moving average price is $35.75 and its two-hundred day moving average price is $40.31. The stock has a market capitalization of $1.90 billion, a PE ratio of -11.47 and a beta of 1.11. Vera Therapeutics has a one year low of $25.99 and a one year high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Analyst Ratings Changes

A number of equities analysts have recently commented on VERA shares. Wedbush lifted their price objective on Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. Guggenheim lifted their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. lifted their target price on Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price on the stock. Finally, Wells Fargo & Company assumed coverage on Vera Therapeutics in a research report on Thursday, November 21st. They set an "overweight" rating and a $70.00 target price on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Vera Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $65.11.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of the firm's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $46.94, for a total transaction of $821,450.00. Following the sale, the chief executive officer now owns 85,942 shares of the company's stock, valued at approximately $4,034,117.48. This trade represents a 16.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders sold 52,500 shares of company stock worth $2,305,625. Insiders own 21.70% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.